Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: Dosing adjustments and increased risk of serious side effects of uric acid lowering agents in patients with reduced renal function lead to undercorrection of hyperuricemia in patients with advanced chronic kidney disease(CKD) and gout. Febuxostat is highly effective and well-tolerated to treat hyperuricemia in CKD patients. Although several evidences demonstrated the usefulness of febuxostat in hyperuricemic CKD patients, clinical studies aimed at the CKD patients with inappropriately controlled hyperuricemia by allopurinol have been relatively lacking. The study objective is to evaluate the safety and efficacy of febuxostat in patients, who had CKD with severe renal impairment and did not meet with the target uric acid levels using allopurinol.
Methods: Data were collected from 168 patients who had CKD with more than stage 3b and changed from allopurinol to febuxostat due to uncontrolled hyperuricemia between 2005 and 2014 at Yonsei University Medical Center. Uric acid and creatinine were analyzed at baseline and during the first 6 and 12 months after conversion of febuxostat. Estimated glomerular filtration rate was calculated using the formula of MDRD equation. The patients were defined as a well-controlled state when the uric acid values of the study subjects reached within 6.0 mg/dL.
Results: The mean age was 60.7±14.6 years, and 129 patients (76.8%) were male. The number of patients was 25 (14.9%) in CKD stage 3b, 75 (44.6%) in stage 4, 8 (4.8%) in stage 5, 38 (22.8%) in patients treated with maintenance dialysis, 22 (13.1%) in patients underwent kidney transplantation. The mean estimated GFR (eGFR) and uric acid levels at baseline was 23.1±17.3 ml/min/1.73m
Conclusion: Present study demonstrated that substantial hyperuricemic CKD patients treated with febuxostat were achieved the target of uric acid levels without adverse events. Febuxostat is an effective and safe uric acid lowering drug in allopurinol-intolerant patients with advanced CKD.
To cite this abstract in AMA style:Oh YJ, Jung SM, Lee SW, Park YB, Song JJ. Safety and Efficacy of Febuxostat in Advanced CKD Patients with Hyperuricemia [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/safety-and-efficacy-of-febuxostat-in-advanced-ckd-patients-with-hyperuricemia/. Accessed December 1, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-efficacy-of-febuxostat-in-advanced-ckd-patients-with-hyperuricemia/